Pharmaceutical companies 

Have improved the efficacy and safety of ADHD drugs over the years by creating novel formulations and delivery systems. In order to reduce drug peaks and troughs and offer more sustained symptom relief, extended-release formulations, such Adderall XR and Concerta, were developed. Alternatives to stimulants, such as atomoxetine (Strattera) and guanfacine (Intuniv), were also created for people with co-occurring disorders or those who could not take them.

Notwithstanding these developments, problems remained. A lot of people have negative effects like mood fluctuations, appetite loss, and insomnia. Furthermore, discussions and disputes among parents and the medical community have been sparked by worries about the long-term consequences of ADHD medication, notably on children’s growth and development.

About The Author